Biosimilar contract manufacturing involves the production of biosimilar drugs by third-party contract manufacturing organizations (CMOs). Biosimilars are biological products that are highly similar to already approved biologic drugs, and contract manufacturing allows companies to outsource the manufacturing process to specialized facilities.
Boehringer Ingelheim expands its biosimilars manufacturing capacity with a new 800 million euro site in Vienna, Austria: This strategic move reinforces their commitment to the biosimilar market and strengthens their European presence.
Samsung Biologics partners with GSK for the manufacturing of GSK's monoclonal antibody and products, including lupus treatments like Benlysta: This collaboration highlights the growing trend of major pharmaceutical companies outsourcing biosimilar manufacturing for improved efficiency and cost-effectiveness.
Lonza signs a multi-year agreement with Amgen for the development and manufacturing of a biosimilar: This deal showcases the increasing demand for reliable and experienced contract manufacturing partners with expertise in biosimilars.
WuXi AppTec launches a new "Center of Excellence" dedicated to biosimilar development and manufacturing in Ireland: This expansion underscores WuXi AppTec's focus on providing comprehensive biosimilar solutions for global clients.
Samsung Biologics opens its third manufacturing facility in South Korea, dedicated to biosimilars and cell therapy products: This investment signals the company's commitment to becoming a leading player in the biosimilar contract manufacturing market.
Fujifilm Diosynth Biotechnologies expands its biomanufacturing capacity in North Carolina, USA: This expansion caters to the rising demand for biosimilar manufacturing in the region and strengthens Fujifilm's position in the North American market.
Biosimilar Contract Manufacturing Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)